Murphy Sabina A, Dauterman Kent, de Lemos James A, Kermgard Sarah, Antman Elliott M, Braunwald Eugene, Gibson C Michael
TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Am Heart J. 2003 Jul;146(1):42-7. doi: 10.1016/S0002-8703(03)00145-5.
In the absence of thrombolytic therapy, patients with non-Q-wave myocardial infarction (MI) have previously been shown to have lower long-term mortality rates than patients with Q-wave MI. The goal of our study was to examine the angiographic and clinical differences between non-Q-wave MI and Q-wave MI in patients with ST elevation MI (STEMI) in the era of thrombolytic and combination therapy of thrombolytics plus glycoprotein IIb/IIIa inhibitors.
Angiography was performed 90 minutes after thrombolytic administration in the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The development of a non-Q-wave MI was assessed on electrocardiogram performed at the time of hospital discharge. Angiographic findings were assessed at an angiographic core laboratory by blinded investigators.
The qualifying episode of ST elevation developed into a non-Q-wave MI in 36% of patients (315/878) and into a Q-wave MI in 64% of patients (563/878). In patients in whom non-Q-wave MI developed, the rate of TIMI grade 3 flow was higher, peak creatine kinase level was lower, mean left ventricular ejection fraction was greater, corrected TIMI frame counts (CTFCs) were lower (ie, faster blood flow), and chest pain duration after thrombolytic administration was shorter. Patients in whom non-Q-wave MI developed less frequently underwent a percutaneous coronary intervention (PCI), and when they did, they had faster post-PCI CTFCs and higher rates of post-PCI TIMI grade 3 flow. Patients in whom a non-Q-wave MI developed had lower rates of severe recurrent ischemia. There were no differences in 30-day or in-hospital mortality rates or recurrent MI between patients with Q-wave MI and patients with non-Q-wave MI.
After thrombolytic therapy in STEMI with or without abciximab, ejection fractions were higher, the duration of ischemia was shorter, and coronary blood flow at both 90 minutes and after PCI was faster in patients who sustained non-Q-wave MI than in patients who sustained Q-wave MI. No differences in mortality or recurrent MI rates were detected in patients who sustained a Q-wave MI and patients in whom a Q-wave MI did not evolve in the modern thrombolytic era.
在没有溶栓治疗的情况下,既往研究表明,非Q波心肌梗死(MI)患者的长期死亡率低于Q波MI患者。我们研究的目的是在溶栓及溶栓联合糖蛋白IIb/IIIa抑制剂治疗的时代,探讨ST段抬高型心肌梗死(STEMI)患者中非Q波MI与Q波MI之间的血管造影及临床差异。
在心肌梗死溶栓治疗(TIMI)14试验中,溶栓给药90分钟后进行血管造影。在出院时进行的心电图检查中评估非Q波MI的发生情况。血管造影结果由不知情的研究人员在血管造影核心实验室进行评估。
ST段抬高的合格发作在36%的患者(315/878)中发展为非Q波MI,在64%的患者(563/878)中发展为Q波MI。在发生非Q波MI的患者中,TIMI 3级血流率更高,肌酸激酶峰值水平更低,平均左心室射血分数更大,校正TIMI帧数(CTFCs)更低(即血流更快),溶栓给药后胸痛持续时间更短。发生非Q波MI的患者较少接受经皮冠状动脉介入治疗(PCI),而当他们接受PCI时,PCI术后CTFCs更快,PCI术后TIMI 3级血流率更高。发生非Q波MI的患者严重复发性缺血发生率更低。Q波MI患者与非Q波MI患者在30天或住院死亡率或再发MI方面没有差异。
在STEMI患者中,无论是否使用阿昔单抗进行溶栓治疗,发生非Q波MI的患者比发生Q波MI的患者射血分数更高,缺血持续时间更短,90分钟时及PCI术后的冠状动脉血流更快。在现代溶栓时代,发生Q波MI的患者与未发展为Q波MI的患者在死亡率或再发MI率方面未检测到差异。